Home › Funds › Deep Track Capital, LP › CLDX
Deep Track Capital, LP position in CLDX
CELLDEX THERAPEUTICS INC NEW · Health Care
Deep Track Capital, LP reported holding 2,125,532 shares of CLDX (CELLDEX THERAPEUTICS INC NEW) in its Q3 2026 13F filing — a position valued at US$68.9M, representing 1.15% of its reported portfolio and ranking #30 among its reported holdings. Deep Track Capital, LP has disclosed CLDX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Deep Track Capital, LP's CLDX position evolved
Deep Track Capital, LP first disclosed a stake in CLDX in Q4 2024 at 1,540,132 shares (US$38.9M). The position peaked in Q2 2026 at 2,939,151 shares, worth US$109.4M. Across 8 filings, Deep Track Capital, LP increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 2,125,532 shares valued at US$68.9M — a reduction of -813,619 shares quarter over quarter.. Notable position changes include a 30% increase in Q1 2025 (shares rose 12% over the following quarter), a 32% trim in Q1 2026 (shares rose 17% over the following quarter), a 129% increase in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 1.54M | $38.92M | New |
| Q1 2025 | 2.00M | $36.30M | Add |
| Q2 2025 | 2.00M | $40.70M | Hold |
| Q3 2025 | 2.00M | $51.74M | Hold |
| Q4 2025 | 1.90M | $51.62M | Reduce |
| Q1 2026 | 1.28M | $40.73M | Reduce |
| Q2 2026 | 2.94M | $109.37M | Add |
| Q3 2026 | 2.13M | $68.89M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CLDX and 13F data
CLDX (CELLDEX THERAPEUTICS INC NEW) is a Health Care company. 39 other funds we track also report a position in CLDX — the largest reported positions include Kynam Capital Management, LP (US$164.2M), EVENTIDE ASSET MANAGEMENT, LLC (US$61.5M), Commodore Capital LP (US$50.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CLDX
- Kynam Capital Management, LP 5.07M sh · $164.19M · Q3 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.90M sh · $61.46M · Q3 2026
- Commodore Capital LP 1.35M sh · $50.23M · Q2 2026
- Bellevue Group AG 1.20M sh · $44.65M · Q2 2026
- BAKER BROS. ADVISORS LP 1.18M sh · $44.00M · Q2 2026
- Novo Holdings A/S 1.02M sh · $38.14M · Q2 2026
- Eversept Partners, LP 1.17M sh · $38.07M · Q3 2026
- Affinity Asset Advisors, LLC 1.16M sh · $37.61M · Q3 2026
- Elmind Capital, LP 990.00K sh · $36.84M · Q2 2026
- Foresite Capital Management VI LLC 879.71K sh · $32.73M · Q2 2026
- ADAR1 Capital Management, LLC 799.30K sh · $25.91M · Q3 2026
- Trails Edge Capital Partners, LP 765.00K sh · $24.79M · Q3 2026
More on Deep Track Capital, LP
FAQ
How long has Deep Track Capital, LP held CLDX?
Deep Track Capital, LP has disclosed CLDX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is Deep Track Capital, LP's current position in CLDX?
As of Q3 2026, Deep Track Capital, LP holds 2.13M shares of CLDX (CELLDEX THERAPEUTICS INC NEW), valued at $68.89M, representing 1.15% of its reported portfolio and ranking #30.
Has Deep Track Capital, LP been buying or selling CLDX?
In the latest 13F filing (Q3 2026), Deep Track Capital, LP reduced its position in CLDX. The position peaked in Q2 2026 at 2.94M shares.
Which other funds hold CLDX?
Other major institutional holders of CLDX include Kynam Capital Management, LP, EVENTIDE ASSET MANAGEMENT, LLC, Commodore Capital LP, among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.